On September 28, CANSINOBIO rose 5.46% in regular trading, trading at 31.92 HKD/share, with turnover of approximately 77.31 million HKD. The gain represents a post-holiday recovery rally following a pullback that came after five consecutive sessions of gains totaling over 25%.

The core catalyst remains the company's earlier announcement that its subsidiary CanSino Shanghai signed a strategic cooperation framework agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines. The partnership targets gastrointestinal solid tumors and rare cancers, spanning early-stage R&D through commercialization. CLSA noted in a research report that CANSINOBIO's mRNA development route and antigen design are broadly comparable to Moderna's, characterizing the collaboration as a platform-level valuation re-rating opportunity.

Fundamentally, the company reported H1 revenue of RMB 550 million, up 43.81% year-over-year, with overseas revenue surging 4,724% to RMB 152 million. Net losses narrowed sharply to near breakeven. The stock had triggered an abnormal trading alert on its A-shares in August after a cumulative three-day gain exceeding 30%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)